Whats Inside: Evidence-Based, Action-Focused This guide bridges the gap between knowing what to doand actually doing it
Strength training is the single most important addition
Eli Lilly and Company 's Retatrutide Shows Up to 28% Weight Loss in Phase-3 Study Eli Lilly reported promising Phase-3 results for #retatrutide, with the triple agonist therapy demonstrating up to 28% weight loss, marking a major milestone in next-generation obesity treatment innovation
Semaglutide has consistently demonstrated better reductions in HbA1c and body weight compared to placebo and a variety of active comparators, including sitagliptin, exenatide extended release, insulin glargine, dulaglutide, canagliflozin, and liraglutide
Schedule a consultation with our Pure Medical Spa team to see how science-backed treatments can help you look and feel your best.